-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 12, the official website of NMPA showed that the listing application of Wanchun Pharmaceutical's Pranabrin Concentrate Solution for Injection is planned to be included in the priority review and approval.
Plinabulin is a small molecule of marine origin and an activator of guanine nucleotide exchange factor (GEF-H1).
In addition, Plinabulin is a non-G-CSF drug that reverses the blocking formation of neutrophils in the bone marrow induced by docetaxel and maintains the level of neutrophils within the normal range.
This listing application is based on positive data from the Phase 3 clinical trial PROTECTIVE-2 study.
The results showed that the trial not only reached the primary endpoint, but also reached all key secondary endpoints.
Note: The original text has been deleted